Fig. 1From: MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)Study schema. Patients are randomised to either panitumumab monotherapy or panitumumab plus infusional 5-FUBack to article page